[Advantage of a new therapeutic agent for respiratory dyspneic diseases].
D001249:Asthma / Q000188:drug therapy*; D001982:Bronchial Diseases / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use; D004417:Dyspnea / Q000188:drug therapy*; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use*; D013806:Theophylline / Q000627:therapeutic use
D001993:Bronchodilator Agents; D010276:Parasympatholytics; D002110:Caffeine; D013806:Theophylline
Intérêt d'une nouvelle thérapeutique des affections dyspnéisantes respiratoires.